Utility of Circulating Tumor DNA Assessment in Characterizing Recurrence Sites after Optimal Resection for Metastatic Colorectal Cancer

• Published in: Journal of the American College of Surgeons Vol. 238; no. 6; pp. 1013 - 1020
• Main Authors: Bansal, Varun V, Belmont, Erika, Godley, Frederick, Dhiman, Ankit, Witmer, Hunter D, Li, Shen, Liao, Andy, Eng, Oliver S, Turaga, Kiran K, Shergill, Ardaman
• Format: Journal Article
• Language: English
• Published: United States 01.06.2024
• Subjects: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor - blood; Biomarkers, Tumor - genetics; Circulating Tumor DNA - blood; Circulating Tumor DNA - genetics; Colorectal Neoplasms - blood; Colorectal Neoplasms - genetics; Colorectal Neoplasms - pathology; Colorectal Neoplasms - surgery; Female; Humans; Liver Neoplasms - blood; Liver Neoplasms - diagnosis; Liver Neoplasms - genetics; Liver Neoplasms - secondary; Liver Neoplasms - surgery; Male; Middle Aged; Neoplasm Recurrence, Local - blood; Neoplasm Recurrence, Local - diagnosis; Peritoneal Neoplasms - blood; Peritoneal Neoplasms - diagnosis; Peritoneal Neoplasms - genetics; Peritoneal Neoplasms - secondary; Peritoneal Neoplasms - surgery; Retrospective Studies
• ISSN: 1072-7515; 1879-1190; 1879-1190
• DOI: 10.1097/XCS.0000000000001028

Plasma circulating tumor DNA (ctDNA) is a promising biomarker for metastatic colorectal cancer (mCRC); however, its role in characterizing recurrence sites after mCRC resection remains poorly understood. This single-institution study investigated the timing of ctDNA detection and its levels in the context of recurrence at different sites after mCRC resection. Patients who underwent optimal resection of CRC metastases involving the peritoneum, distant lymph nodes, or liver, with serial postoperative tumor-informed ctDNA assessments (Signatera) were included. Recurrence sites, as defined by surveillance imaging or laparoscopy, were categorized as peritoneal-only and other distant sites (liver, lung, lymph nodes, or body wall). Among the 31 included patients, ctDNA was detected in all 26 (83.4%) patients with postoperative recurrence and was persistently undetectable in 5 patients who did not experience recurrence. At 3 months postsurgery, ctDNA was detected in 2 (25%) of 8 patients with peritoneal-only recurrence and 17 (94.4%) of 18 patients with distant recurrence (p < 0.001). Beyond 3 months, ctDNA was detected in the remaining 6 patients with peritoneal-only disease and 1 patient with distant disease. ctDNA detection preceded the clinical diagnosis of recurrence by a median of 9 weeks in both groups. At recurrence, peritoneal-only recurrent cases exhibited lower ctDNA levels (median 0.4 mean tumor molecules/mL, interquartile range 0.1 to 0.8) compared with distant recurrence (median 5.5 mean tumor molecules/mL, interquartile range 0.8 to 33.3, p = 0.004). Peritoneal-only recurrence was associated with delayed ctDNA detection and low levels of ctDNA after optimal resection for mCRC. ctDNA testing may effectively characterize recurrence sites and may help guide subsequent treatments specific to the disease sites involved.